ITGB2 and neoplasm: The overexpression of ITGB2 in TNBC tissues and serum EVs is linked to poorer patient outcomes, and its role in CAF activation and immune modulation suggests that targeting ITGB2 could disrupt key tumor‐stroma interactions and enhance the effectiveness of existing therapies, but it is likely that other EV‐derived messengers also contribute to this process.